Biogen Idec is considering buyout offers after billionaire investor Carl Icahn and other potential buyers have expressed interest in acquiring the company. Biogen is one of the largest biotechnology companies that has been dealing with slowing growth for its primary product, a multiple sclerosis drug, Avonex.